<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432023000100172</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v6i16.216</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamientos empleados para el síndrome de Dravet]]></article-title>
<article-title xml:lang="en"><![CDATA[Treatments used for Dravet syndrome]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tratamentos usados para a síndrome de Dravet]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerrero]]></surname>
<given-names><![CDATA[María Cielo Duran]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[Juan Carlos Pozo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<volume>6</volume>
<numero>16</numero>
<fpage>172</fpage>
<lpage>182</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432023000100172&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432023000100172&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432023000100172&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se estima que el síndrome de Dravet (SD) es una encefalopatía epiléptica y de desarrollo grave, que ocurre en 1 de cada 15000 nacidos vivos. Se caracteriza por una epilepsia resistente a los medicamentos que se presenta en el primer año de vida con convulsiones prolongadas acompañadas de fiebre o cambios de temperatura, a menudo de naturaleza hemiclónica, seguidas de convulsiones no provocadas de diversos tipos. Objetivo. Describir los tratamientos empleados para el Síndrome de Dravet. Metodología. Se realizó una revisión sistemática. Para ello, se ejecutó una búsqueda en múltiples bases de datos, como Pubmed, Dialnet, Sciencedirect, Scielo y Scopus. La búsqueda se limitó a los artículos publicados desde el año 2017 hasta el 2022. Después de recopilar los artículos, se aplicaron varios criterios de filtrado para asegurarse de que sólo se incluyeran aquellos estudios que eran pertinentes para el análisis. Conclusión. Los tratamientos actuales, como los medicamentos antiepilépticos, las dietas cetogénicas y la estimulación nerviosa, han demostrado ser efectivos para reducir la frecuencia y la gravedad de las convulsiones en los pacientes. Es importante que los pacientes y sus cuidadores trabajen en conjunto con un equipo médico para lograr la mejor gestión posible de la enfermedad. Aunque no se dispone de una cura definitiva para el Síndrome de Dravet, los avances médicos continúan proporcionando esperanza y opciones de tratamiento a los pacientes y sus familias.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Dravet syndrome (DS) is estimated to be a severe developmental and epileptic encephalopathy, occurring in 1 in 15000 live births. It is characterized by drug-resistant epilepsy presenting in the first year of life with prolonged seizures accompanied by fever or temperature changes, often hemiclonic in nature, followed by unprovoked seizures of various types. Objective. To describe the treatments used for Dravet syndrome. Methodology. A systematic review was performed. For this purpose, a search was carried out in multiple databases, such as Pubmed, Dialnet, Sciencedirect, Scielo and Scopus. The search was limited to articles published from 2017 to 2022. After collecting the articles, several filtering criteria were applied to ensure that only those studies that were relevant to the analysis were included. Conclusion. Current treatments, such as antiepileptic drugs, ketogenic diets, and nerve stimulation, have been shown to be effective in reducing the frequency and severity of seizures in patients. It is important that patients and their caregivers work together with a medical team to achieve the best possible management of the disease. Although there is no definitive cure for Dravet syndrome, medical advances continue to provide hope and treatment options for patients and their families.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO Estima-se que a síndrome de Dravet (SD) seja uma encefalopatia epiléptica e de desenvolvimento grave, que ocorre em 1 a cada 15.000 nascidos vivos. Caracteriza-se por epilepsia resistente a medicamentos que se apresenta no primeiro ano de vida com convulsões prolongadas acompanhadas de febre ou alterações de temperatura, muitas vezes de natureza hemiclônica, seguidas de convulsões não provocadas de vários tipos. Objetivo. Descrever os tratamentos usados para a síndrome de Dravet. Metodologia. Foi realizada uma revisão sistemática. Para isso, foi realizada uma pesquisa em vários bancos de dados, como Pubmed, Dialnet, Sciencedirect, Scielo e Scopus. A pesquisa foi limitada a artigos publicados de 2017 a 2022. Após a coleta dos artigos, vários critérios de filtragem foram aplicados para garantir que apenas os estudos relevantes para a análise fossem incluídos. Conclusão. Os tratamentos atuais, como medicamentos antiepilépticos, dietas cetogênicas e estimulação nervosa, demonstraram ser eficazes na redução da frequência e da gravidade das convulsões nos pacientes. É importante que os pacientes e seus cuidadores trabalhem em conjunto com uma equipe médica para obter o melhor controle possível da doença. Embora não haja uma cura definitiva para a Síndrome de Dravet, os avanços médicos continuam a oferecer esperança e opções de tratamento para os pacientes e suas famílias.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Terapéutica]]></kwd>
<kwd lng="es"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[Epilepsia]]></kwd>
<kwd lng="en"><![CDATA[Therapeutics]]></kwd>
<kwd lng="en"><![CDATA[Diagnosis]]></kwd>
<kwd lng="en"><![CDATA[Epilepsy]]></kwd>
<kwd lng="pt"><![CDATA[Terapêutica]]></kwd>
<kwd lng="pt"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="pt"><![CDATA[Epilepsia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Onofrio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Amadori]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tripodi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Balagura]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Iurilli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Current and promising therapeutic options for Dravet syndrome. Expert Opinion on Pharmacotherapy.]]></source>
<year>2022</year>
<volume>23</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1727-36</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isom]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Knupp]]></surname>
<given-names><![CDATA[KG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2021</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1524-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Deighton]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Vila]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Szabo]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Maru]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gofshteyn]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical, economic, and humanistic burden of Dravet syndrome - A systematic literature review]]></article-title>
<source><![CDATA[Epilepsy &amp; Behavior]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Burgess]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Malone]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Glubb]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Helbig]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Vadlamudi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic epilepsy with febrile seizures plus: Refining the spectrum]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2017</year>
<volume>89</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berecki]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bryson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Terhag]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maljevic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gazina]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SCN1A gain of function in early infantile encephalopathy]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>2019</year>
<volume>85</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>514-25</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Lange]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Gunning]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sonsma]]></surname>
<given-names><![CDATA[ACM]]></given-names>
</name>
<name>
<surname><![CDATA[van Gemert]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[van Kempen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verbeek]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A -related seizure phenotypes]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2018</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1154-65</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadleir]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Mountier]]></surname>
<given-names><![CDATA[EI]]></given-names>
</name>
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[DeVile]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2017</year>
<volume>89</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1035-42</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strzelczyk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schubert-Bast]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic advances in Dravet syndrome: a targeted literature review]]></article-title>
<source><![CDATA[Expert Review of Neurotherapeutics]]></source>
<year>2020</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1065-79</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Mingorance]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruban-Fell]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Newell]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vyas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder. Front Neurol]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wirrell]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Nabbout]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Recent Advances in the Drug Treatment of Dravet Syndrome. CNS Drugs]]></source>
<year>2019</year>
<volume>33</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>867-81</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Isquith]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Gioia]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Gammaitoni]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Farfel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Galer]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.]]></article-title>
<source><![CDATA[Epilepsy &amp; Behavior]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoonjans]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ceulemans]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.]]></article-title>
<source><![CDATA[Expert Review of Neurotherapeutics]]></source>
<year>2022</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>351-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kariuki]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Abubakar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Newton CRJC. Prevalence, causes, and behavioral and emotional comorbidities of acute symptomatic seizures in Africa: A critical review]]></article-title>
<source><![CDATA[Epilepsia Open]]></source>
<year>2017</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-19</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical spectrum and the comorbidities of Dravet syndrome in Taiwan and the possible molecular mechanisms.]]></article-title>
<source><![CDATA[Sci Rep.]]></source>
<year>2021</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schubert-Bast]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wyatt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenow]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data]]></article-title>
<source><![CDATA[Epilepsy &amp; Behavior]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bjurulf]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Reilly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sigurdsson]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Thunström]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kolbjer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hallböök]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dravet syndrome in children-A population-based study.]]></article-title>
<source><![CDATA[Epilepsy Research]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owen Pickrell]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Guelfucci]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[RFM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and healthcare resource utilization of patients with Dravet syndrome: Retrospective linkage cohort study]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Scheffer]]></surname>
<given-names><![CDATA[IE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining Dravet syndrome: An essential pre&#8208;requisite for precision medicine trials.]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2021</year>
<volume>62</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2205-17</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strzelczyk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kurlemann]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bast]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bettendorf]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Kluger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome.]]></article-title>
<source><![CDATA[Neurol Res Pract]]></source>
<year>2022</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anwar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saleem]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[UK]]></given-names>
</name>
<name>
<surname><![CDATA[Arumaithurai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Dravet Syndrome: An Overview. Cureus Internet]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selvarajah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zulfiqar-Ali]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[DM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of adults with Dravet syndrome.]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esterhuizen]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Mefford]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Ramesar]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carvill]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Wilmshurst]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dravet syndrome in South African infants: Tools for an early diagnosis.]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Coryell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saneto]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Grinspan]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kekis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early-Life Epilepsies and the Emerging Role of Genetic Testing.]]></article-title>
<source><![CDATA[JAMA Pediatr]]></source>
<year>2017</year>
<volume>171</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
